文献速递慢性肾脏病血液净化与透析

2型糖尿病合并CKD患者抗促红细胞生成素受体抗体与临床结局:CREDENCE试验事后分析

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial.
PubMed 文献 · Kidney Int Rep · 2023-12-01

本研究基于CREDENCE试验事后分析,在2600例2型糖尿病合并CKD患者中检测抗促红细胞生成素受体抗体,发现7.3%阳性;抗体水平升高与复合肾脏和心血管结局、心血管死亡及全因死亡风险增加相关;卡格列净升高血红蛋白和红细胞压积的效应不受抗体状态影响。

要点

  • 2型糖尿病合并CKD患者中抗EPOR抗体阳性率为7.3%。
  • 抗EPOR抗体水平升高与复合肾脏和心血管结局及死亡风险增加独立相关。
  • 卡格列净升高血红蛋白和红细胞压积的效应与抗EPOR抗体状态无关。

核心结论

  • 在2型糖尿病合并CKD患者中,抗EPOR抗体与复合肾脏和心血管结局、心血管死亡及全因死亡相关。
  • 卡格列净升高血红蛋白和红细胞压积,且不受抗EPOR抗体影响。

研究设计与样本

  • CREDENCE试验的事后分析,患者随机接受卡格列净或安慰剂。
  • 2600例有生物样本的2型糖尿病合并CKD患者,采用酶联免疫吸附法检测血清抗EPOR抗体。
  • 主要结局为血清肌酐加倍、终末期肾病或肾脏/心血管死亡;次要结局包括心血管死亡和全因死亡。
  • 采用多变量Cox回归估计抗体与结局的关联,重复测量混合效应模型评估卡格列净对血红蛋白和红细胞压积的影响。

主要发现

  • 2600例参与者中191例(7.3%)抗EPOR抗体阳性。
  • 基线抗EPOR抗体每升高1个标准差,主要结局风险增加(HR=1.12,95%CI 1.01-1.24,P=0.04)。
  • 抗EPOR抗体每升高1个标准差,心血管死亡风险增加(HR=1.27,95%CI 1.08-1.48,P<0.01)。
  • 抗EPOR抗体每升高1个标准差,全因死亡风险增加(HR=1.26,95%CI 1.11-1.43,P<0.01)。
  • 卡格列净较安慰剂升高血红蛋白7.0 g/l(95%CI 6.2-7.9)和红细胞压积2.4%(95%CI 2.2-2.7)。

关键数值与推荐

  • 抗EPOR抗体阳性定义为酶联免疫吸附法检测阳性,阳性率7.3%(191/2600)。
  • 主要结局HR(每1-SD抗体升高)=1.12,95%CI 1.01-1.24,P=0.04。
  • 心血管死亡HR(每1-SD抗体升高)=1.27,95%CI 1.08-1.48,P<0.01。
  • 全因死亡HR(每1-SD抗体升高)=1.26,95%CI 1.11-1.43,P<0.01。
  • 卡格列净升高血红蛋白7.0 g/l(95%CI 6.2-7.9),升高红细胞压积2.4%(95%CI 2.2-2.7)。

临床怎么用

  • 在2型糖尿病合并CKD患者中,抗EPOR抗体可能有助于识别肾脏和心血管结局及死亡风险较高的个体。
  • 卡格列净升高血红蛋白和红细胞压积的效应不受抗EPOR抗体状态影响,支持其在该人群中的使用。

局限性

  • 本研究为CREDENCE试验的事后分析,结果需前瞻性验证。
  • 仅2600例有生物样本的参与者纳入分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autoantibodies to erythropoietin receptor (anti-EPOR antibodies) have been identified in patients with various kidney diseases. However, data in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) is limited. We assessed the prevalence of anti-EPOR antibodies and their association with clinical outcomes in this population. METHODS: The CREDENCE randomized patients with T2D and CKD to canagliflozin or placebo. Serum anti-EPOR antibodies, the exposure of interest, were measured using enzyme-linked immunosorbent assay. The primary outcome was doubling of serum creatinine, end-stage kidney disease, or death from kidney or cardiovascular (CV) causes. Secondary outcomes included CV and all-cause mortality. Multivariable Cox-regression models estimated associations between anti-EPOR antibodies and outcomes. The effects of canagliflozin on hemoglobin and hematocrit, stratified by the presence of anti-EPOR antibodies were assessed with a repeated measures mixed effects model. RESULTS: Of 2600 participants with available biosamples, 191 (7.3%) were positive for anti-EPOR antibodies. Higher baseline anti-EPOR antibodies were associated with increased risk of primary outcome (hazard ratio [HR] per 1-SD increase = 1.12, 95% confidence interval [CI] = 1.01-1.24, P = 0.04), with CV death (HR = 1.27, 95% CI = 1.08-1.48, P < 0.01) and all-cause mortality (HR = 1.26, 95% CI = 1.11-1.43, P < 0.01). During follow-up, canagliflozin, compared to placebo, increased hemoglobin and hematocrit by 7.0 g/l (95% CI = 6.2-7.9) and 2.4% (2.2-2.7), respectively. These effects were consistent across patients with and without anti-EPOR antibodies (P-interaction = 0.24 and 0.36, respectively). CONCLUSION: In patients with T2D and CKD, anti-EPOR antibodies were associated with the composite kidney and CV outcome, as well as CV and all-cause mortality. Canagliflozin increased hemoglobin and hematocrit regardless of anti-EPOR antibodies.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Koshino A, Neuen BL, Oshima M, et al. Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial. Kidney Int Rep. 2023. PMID: 38344715. doi:10.1016/j.ekir.2023.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。